These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 22182920

  • 1. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
    Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD.
    Leukemia; 2012 May; 26(5):985-90. PubMed ID: 22182920
    [Abstract] [Full Text] [Related]

  • 2. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.
    Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
    [Abstract] [Full Text] [Related]

  • 3. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
    Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A.
    Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
    Saglio G, Fava C.
    Leuk Lymphoma; 2009 Oct; 50(10):1564-5. PubMed ID: 19757319
    [No Abstract] [Full Text] [Related]

  • 7. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P, Ma D, Yu Z, Zhe N, Ren M, Wang P, Yu M, Huang J, Fang Q, Wang J.
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P.
    Oncotarget; 2014 Oct 15; 5(19):8947-58. PubMed ID: 25333254
    [Abstract] [Full Text] [Related]

  • 10. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
    Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.
    Mol Cancer Ther; 2008 Jan 15; 7(1):48-58. PubMed ID: 18202009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O, Kuepper MK, Bütow M, Costa IG, Appelmann I, Beier F, Luedde T, Braunschweig T, Koschmieder S, Brümmendorf TH, Schemionek M.
    BMC Cancer; 2019 Jul 04; 19(1):658. PubMed ID: 31272418
    [Abstract] [Full Text] [Related]

  • 15. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
    Vianello F, Villanova F, Tisato V, Lymperi S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley J, Lam EW, Dazzi F.
    Haematologica; 2010 Jul 04; 95(7):1081-9. PubMed ID: 20179085
    [Abstract] [Full Text] [Related]

  • 16. Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
    Herrmann AB, Müller ML, Orth MF, Müller JP, Zernecke A, Hochhaus A, Ernst T, Butt E, Frietsch JJ.
    J Cell Mol Med; 2020 Mar 04; 24(5):2942-2955. PubMed ID: 31957290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.